WT1 and acute myeloid leukemia: Long-term survival (more than 8 years) was reported in three out of eight patients with high-risk disease (two relapsed, one secondary AML) with minimal residual disease persistence measured through WT1 RNA in bone marrow (BM) or peripheral blood (PB) [14].